Belite Bio, Inc
BLTEHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. The company carries a $7.80B market cap, placing it firmly in the mid-cap category. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Market Cap
$7.80B
Beta
-1.24
P/E (TTM)
—
P/E (Fwd)
100.64
EPS (TTM)
$-2.73
EPS (Fwd)
$1.92
ROE
-22.1%
ROA
-15.7%
Cash
—
Total Debt
$0
Free CF
—
52W Change
194.8%
Annual Financials
Cash vs Debt
Where BLTE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BLTE finished 0.51% above its 150-day moving average ($159.84) and 2.18% above its 200-day moving average ($157.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLTE overbought or oversold?
At the September 3, 2026 close, BLTE's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Belite Bio, Inc carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. ROE of -22.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
BLTE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Belite Bio, Inc's trajectory.